Business Wire

MERCY-SHIPS

31.5.2022 07:32:04 CEST | Business Wire | Press release

Share
H.E. President Macky Sall Leads Inauguration of the World’s Largest Purpose-built Hospital Ship, the Global Mercy™

H.E. President of Senegal Macky Sall has inaugurated the world’s largest purpose-built hospital ship and committed to accelerate access to surgical, obstetric and anesthetic care for the nations of Africa. Ceremonies commemorated more than 30 years of service in Africa. International humanitarian organization Mercy Ships and its partners in Africa used the opportunity to come together in an unprecedented and strategic effort to improve access to safer surgery across the continent through a series of milestone events.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220530005472/en/

Representatives from Cameroon, the Union of Comoros, Congo Brazzaville, The Gambia, Guinea-Bissau, and Senegal, gathered on board the Global Mercy to approve a strategic road map to improve surgical care for African nations by 2030, where an estimated 93% of sub-Saharan Africa still lack access to safe surgery.

H.E. President Macky Sall greeted the Heads of State, saying, “We, heads of states present this day, have adopted the Dakar Declaration, which is the result of the meticulous work of our ministers and experts on access to surgical, obstetric and aesthetic care. As President in Office for the African Union, I commit to bring the Dakar Declaration to the summit of heads of state and African governments.”

Gert van de Weerdhof, Mercy Ships Chief Executive Officer said, “At the end of a difficult week for Senegal and for all of us after the tragic events that happened; today, I want to greet you all on this special day here in Dakar, Senegal. The inauguration of the Global Mercy is only one part of the reason we celebrate today. Big decisions have been made here in Dakar.”

President of the Union of the Comoros, Azali Assoumani said, “I pay tribute to Senegal as well as the personnel of Mercy Ships for their commitment to this mission. I applaud this model cooperation contributing to the strengthening of our surgical, obstetric, and anesthetic systems in Africa.”

The Dakar Declaration is an historic agreement following foundational discussions from an International Symposium in Senegal held May 4 – 6, 2022 where experts and ministers of health from 29 African nations met to put forward their commitment to advancing access to surgical, obstetric, and anesthetic care. The result of the Symposium brought a fresh initiative to draft a clear path toward safer and wider access to surgical care in Africa by 2030. Symposium members shared knowledge of their countries’ surgical care situations, addressed gaps and challenges in their national surgical, obstetric and anesthetic plans, and developed new strategies for implementation and capacity building. Prior to the International Symposium, a baseline assessment was carried out with each country and evaluated by a scientific committee.

A first of its kind in Africa, this study has so far collected data about the availability, access, and operation of surgical, obstetric, and anesthetic healthcare systems in 29 of the 47 nations of WHO’s sub-Saharan African region. The survey provides critical insights into Africa’s healthcare systems from the perspective of district hospitals, particularly in the area of surgery. The World Health Organization will leverage the results of the study to complete the ongoing situational analysis of clinical and hospital services, as well as develop and finalize the regional strategy for strengthening clinical and hospital services in Africa.

The comprehensive preliminary report developed by members of the scientific committee led to the drafting of a roadmap to scale up investment in the strengthening of surgical, obstetric, anesthetic, and nursing care in Africa, in line with the Sustainable Development Goals (SDG). A draft Dakar Declaration was prepared and endorsed by the Ministers of Health and approved by visiting African Heads of State.

The new hospital ship, Global Mercy ™ is 174 meters long, 28.6 meters wide and has space for 200 patients, six operating rooms, one laboratory, general outpatient clinics, a dental clinic, and an eye clinic. The hospital decks cover a total area of 7,000 square meters and contain the latest training facilities. When in full service, the ship will be able to accommodate up to 950 people when docked, including crew members and volunteers from all over the world.

A recording of the inauguration ceremony can be found here: https://www.youtube.com/watch?v=HylOGBYaX-0 .

ABOUT MERCY SHIPS:

Global health for the last two decades has focused on individual diseases, while surgical care in low-resource countries has not received the attention it needs. Lack of surgical care resulted in almost 17 million deaths annually.

Mercy Ships is an international faith-based organization that operates hospital ships to deliver free, world-class healthcare services, medical capacity building, and health system strengthening to those with little access to safe surgical care. Since 1978, Mercy Ships has worked in more than 55 countries, with the last three decades focused entirely on partnering with African nations. Each year, volunteer professionals from over 60 countries serve on board the world’s two largest non-governmental hospital ships, the Africa Mercy® and the Global Mercy™. Professionals such as surgeons, dentists, nurses, health trainers, cooks, and engineers dedicate their time and skills to the cause. Mercy Ships has offices in 16 countries and an Africa Bureau. For more information, visit mercyships.org and follow us @MercyShips on social media.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 12:00:00 CET | Press release

Improvements in symptoms of pain, stiffness, and range of motion were sustained through two yearsTumor responses remained robust1 and durable2Not intended for U.K.-, U.S.- or Canada-based media Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022

WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 11:30:00 CET | Press release

Second limited-edition WHOOP x SR_A collection brings “performance for life” to new WHOOP bands, technical apparel, outerwear, and accessories designed for movement across city and rural environments. WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural wo

Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 11:28:00 CET | Press release

Oral-B iO helps you avoid new tooth and gum issues—and if you have existing gum problems, it can resolve them quicker than a manual toothbrush. Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release

Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates

Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye